Compounds for the treatment of atropic vaginitis

Castelo-Branco, Camil; Cancelo, Marı́a Jesús

doi:10.1517/13543770802564464

Cited by 6 publications

(4 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only a quarter of women with VVA seek treatment [2]. Women with VVA may experience symptoms such as dryness, irritation, itching, burning, and dyspareunia [3]. The VVA is often due to the estrogen deficiency after menopause and may negatively affect the quality of life [1].…”

Section: Introductionmentioning

confidence: 99%

The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial

et al. 2020

View full text Add to dashboard Cite

Background: Around 90% of postmenopausal women are suffering from vaginal atrophy. This study aimed to evaluate the effect of oxytocin vaginal gel on vaginal atrophy among postmenopausal women. Methods: This was a randomized controlled trial that was conducted on 96 postmenopausal women who suffered from vaginal atrophy. The inclusion criteria were: literate women, age 40-60, at least 1 year passed from their last menstrual period or the level of FSH > 40 IU, monogamous women with the sexual relationship. Women in the intervention group, requested to use one applicator of 400 IU oxytocin gel per night and women in the placebo group used placebo each night. The subjective symptoms of vaginal atrophy, vaginal PH, maturation index were measured before and after the intervention. Results: The number of superficial cells was increased significantly in the oxytocin group compared to placebo (38.7 ± 7.18 vs. 3.69 ± 2.76, p = 0.0001), while the number of parabasal cells was decreased significantly in the oxytocin compared to placebo after the intervention. The improvement of the maturation index was more dominant in the oxytocin group (increased from 7.76 ± 4.68 to 52.48 ± 7.54) in comparison to the placebo group (increased from 8.58 ± 4.35 to 13.25 ± 5.06). The PH of the vagina decreased significantly in the oxytocin group in comparison to the placebo group (p = 0.0001). After 8 weeks, 88.6 and 7.1% of women in the oxytocin and placebo groups did not show the severe symptoms of vaginal atrophy (p = 0.001). Conclusion: The results of this study showed that eight-week intervention with oxytocin vaginal gel (400 IU) could significantly improve the vaginal maturation index, subjective symptoms of vaginal atrophy and reduce the PH of the vagina. Using this medication in women who have a contraindication for hormone therapy is recommended. Trial registration: IRCT20160602028220N2.

show abstract

Section: Introductionmentioning

confidence: 99%

The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In these cases, VVA may resolve spontaneously when estrogen levels are restored [2]. VVA symptoms are all dependent from decreased estrogenization and include: Dryness, soreness, irritation and dyspareunia with increased urinary frequency, urgency, and urge incontinence [3]. Clinical findings include the presence of pale and dry vulvovaginal mucosa with petechiae.…”

Section: Introductionmentioning

confidence: 99%

Treatment of Vaginal Atrophy with the Aqueous Extract of Triticum vulgare: Comparison between Different Pharmaceutical Forms

2020

ARCH Women Health Care

View full text Add to dashboard Cite

first-line treatment of VVA is a continuous sexual relationship, using non-hormonal lubricant over the counter vaginal [6]. The systemic and local estrogen administration is recommended for the treatment of VVA in postmenopausal women [7]. Although hormone therapy may alleviate the short and long term complications of menopause, such as hot flashes, night sweats, and VVA, it may increase the risk of breast and endometrial cancer [8]. Because of the adverse effects of estrogen therapy, some women prefer not to use this method for alleviating VVA, and they tend to use non-hormonal medication for this matter [9]. In this regard, it is noteworthy the evidence that a local treatment based on hyaluronic acid is more effective than hormonal therapy in improving VVA symptoms [10]. More recently, it has been showed that the aqueous extract of Triticum vulgare (TVE) in cream [11] and pessaries [12] formulation could reduce sign and symptoms of VVA in postmenopausal women. TVE containing mainly poly/ oligosaccharides' components has been extensively used in different pharmaceutical forms. The Damor Farmaceutici TVE, because of its global patent based on its production process, has unique characteristics that lead to its application in VVA treatment. In fact,

show abstract

“…Vaginal dryness due to hypoestrogenism can be accompanied by itching, burning, discharge, and dyspareunia. 2 Some women also develop fear of pelvic examinations. Frequency of occurrence of VVA, severity of pathological changes, and clinical course of the disease depend on the duration of postmenopause.…”

Section: Introductionmentioning

confidence: 99%

Current treatment options for postmenopausal vaginal atrophy

Naumova

Castelo-Branco

2018

IJWH

Self Cite

106

View full text Add to dashboard Cite

Vulvovaginal atrophy (VVA) is a silent epidemic that affects up to 50%–60% of postmenopausal women who are suffering in silence from this condition. Hormonal changes, especially hypoestrogenism inherent in menopause, are characterized by a variety of symptoms. More than half of menopausal women are concerned about the symptoms of VVA, such as dryness, burning, itching, vaginal discomfort, pain and burning when urinating, dyspareunia, and spotting during intercourse. All these manifestations significantly reduce the quality of life and cause discomfort in the sexual sphere. However, according to research, only 25% of patients with the symptoms of VVA receive adequate therapy. This is probably due to the lack of coverage of this problem in the society and the insufficiently active position of specialists in the field of women’s health regarding the detection of symptoms of VVA. Many patients are embarrassed to discuss intimate complaints with a specialist, which makes it difficult to verify the diagnosis in 75% of cases, and some patients regard the symptoms of VVA as manifestations of the natural aging process and do not seek help. Modern medicine has in the arsenal various options for treating this pathological condition, including systemic and topical hormone replacement therapy, the use of selective estrogen receptor modulators, vaginal dehydroepiandrosterone, use of lubricants and moisturizers, as well as non-drug therapies. Timely diagnosis and adequately selected therapy for the main symptoms of VVA lead to restoration and maintenance of the vaginal function and vaginal health.

show abstract

Compounds for the treatment of atropic vaginitis

Cited by 6 publications

References 60 publications

The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial

The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial

Treatment of Vaginal Atrophy with the Aqueous Extract of Triticum vulgare: Comparison between Different Pharmaceutical Forms

Current treatment options for postmenopausal vaginal atrophy

Contact Info

Product

Resources

About